NeurOp

Executive Summary

NeurOp, Inc. is a clinical-stage biotechnology company headquartered in Atlanta, Georgia, focused on developing novel small molecule therapeutics targeting the NMDA receptor for central nervous system (CNS) disorders. Founded in 2007, the company aims to address significant unmet needs in pain, stroke, subarachnoid hemorrhage, and treatment-resistant depression. Its lead candidate, NP10679, is currently in Phase 1 clinical trials, representing a potentially differentiated approach to modulating NMDA receptor activity with improved safety and tolerability compared to existing agents. Despite being private with limited disclosed funding, NeurOp’s long development history suggests a focused, capital-efficient strategy. The company’s ability to advance NP10679 through early-stage trials and secure partnerships will be critical for future success. NeurOp operates in a competitive CNS landscape, but its NMDA receptor platform could offer advantages in both efficacy and side-effect profiles. Key upcoming catalysts include the completion and data readout from Phase 1 studies for NP10679, which could validate its therapeutic potential and pave the way for Phase 2 trials in specific indications. Additionally, the company may seek strategic collaborations with larger pharmaceutical firms to accelerate development and provide non-dilutive funding. A third catalyst could be the advancement of preclinical candidates for other CNS indications, broadening its pipeline. Given the early stage, conviction is moderate, but success in Phase 1 would significantly de-risk the platform and increase valuation prospects.

Upcoming Catalysts (preview)

• H1 2027Phase 1 clinical data readout for NP1067960% success
• H2 2026Potential partnership or licensing deal40% success
• H2 2027Initiation of Phase 2 trial in a lead indication50% success